Brazilian firm Uniao Quimica plans to make Russian Sputnik V next week

Published On 2021-01-10 03:30 GMT   |   Update On 2021-01-10 03:31 GMT

Brasilia: Brazilian pharmaceutical company Uniao Quimica plans to start producing Russia's Sputnik V vaccine for COVID-19 in Brazil as soon as next week and make up to 8 million doses a month, its international business director Rogerio Rosso said on Friday.

The private company, with a vaccine facility in Brasilia, is preparing to request emergency use authorization from health regulator Anvisa for the vaccine developed in Moscow.

Uniao Quimica last week requested approval to conduct Phase III clinical trials in Brazil, which is required for licensing of the vaccine in the country.

"We await Anvisa authorization to start the clinical studies here," Rosso told Reuters.

Uniao Quimica is working with the Russian Direct Investment Fund (RDIF), which is marketing Sputnik V worldwide, to obtain emergency use authorization that would allow the vaccine to be included in Brazil's nation vaccination plan set to start by the end of the month.

"Next week we will start producing the vaccine. Our plan is to very quickly reach 8 million doses per month," Rosso said.

The governments of Brazilian states of Bahia, Parana and PIaui will partner with the company in undertaking the clinical tests, he said.

Read also: World looking to India for COVID Vaccines: Pharma Experts

RDIF has said it would like to produce the two-shot vaccine in Brazil for export to other countries in Latin America.

Argentina began vaccinating its citizens last week with imported doses of Sputnik V, the only vaccine so far being administered in that country.

Read also: Sputnik V working on trials to increase efficacy of AstraZeneca vaccine to over 90 percent



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News